BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/16/2023 9:24:22 AM | Browse: 83 | Download: 208
 |
Received |
|
2022-12-04 14:05 |
|
Peer-Review Started |
|
2022-12-04 14:07 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-07 09:04 |
|
Revised |
|
2023-02-17 18:08 |
|
Second Decision |
|
2023-04-06 03:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-06 07:57 |
|
Articles in Press |
|
2023-04-06 07:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-04-25 07:43 |
|
Publish the Manuscript Online |
|
2023-05-16 09:24 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Case Report |
| Article Title |
Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mei-Juan Gao, Yan Xu and Wen-Bo Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mei-Juan Gao, MD, Chief Physician, Department of Endocrinology, Peking University Shougang Hospital, No. 9, Jinyuanzhuang Road, Beijing 100041, China. gmjluhe@163.com |
| Key Words |
Immune checkpoint inhibitor; Programmed cell death protein 1 ligand; Autoimmune polyendocrine syndrome type II; Type 1 diabetes mellitus; Thyroiditis; Crohn’s disease; Case report |
| Core Tip |
We report a rare case of multi-system damage induced by cancer therapy with protein 1 ligand inhibitor teriprizumab. A man with squamous cell carcinoma of oropharynx on a combination regimen of teriprizumab, docetaxel, and cisplatin developed autoimmune polyendocrine syndrome type II (APS-2) including thyroiditis and type 1 diabetes mellitus (T1DM) and Crohn’s disease (CD). This case report highlights the possibility of chronic immune toxicities and the long-term implications of cancer immunotherapy. To the best of our knowledge, this is the first reported case of concurrent atypical APS-2 (including T1DM and thyrotoxicosis) and CD in a patient receiving immunotherapy for metastatic nasopharyngeal carcinoma. |
| Publish Date |
2023-05-16 09:24 |
| Citation |
Gao MJ, Xu Y, Wang WB. Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report. World J Clin Cases 2023; 11(14): 3267-3274 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i14/3267.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i14.3267 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
